Universität zu Köln

Journal Article

Degenhardt, Tom, Kreipe, Hans Heinrich, Gluz, Oleg, Kates, Ronald E., Liedtke, Cornelia, Kraemer, Stefan, Clemens, Michael R., Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Stefek, Andrea, Heyl, Volker, Wuerstlein, Rachel, Nitz, Ulrike, Harbeck, Nadia and Christgen, Matthias (2016). Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Pelz, Enrico, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia (2020). Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. Int. J. Cancer, 146 (1). S. 262 - 272. HOBOKEN: WILEY. ISSN 1097-0215

Gluz, Oleg, Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Pelz, Enrico, Clemens, Michael, Warm, Matthias, Aktas, Bahriye, Kuemmel, Sherko, Pare, Laia, Krabisch, Petra, Kreipe, Hans Heinrich, Wuerstlein, Rachel, Nitz, Ulrike and Harbeck, Nadia (2018). Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial. Cancer Res., 78 (4). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Kraemer, Stefan, Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Liedtke, Cornelia, Svedman, Christer, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2016). Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kuemmel, Sherko, Holtschmidt, Johannes, Priel, Jan, Hartkopf, Andreas, Potenberg, Jochem, Luedtke-Heckenkamp, Kerstin, Just, Marianne, Wuelfing, Pia, Von Schumann, Raquel, Graeser, Monika, Wuerstlein, Rachel, Kates, Ronald E., Kreipe, Hans Heinrich and Harbeck, Nadia (2020). De-escalated chemotherapy versus endocrine therapy plus pertuzumab plus trastuzumab for HR+/HER2+early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jozwiak, Katarzyna ORCID: 0000-0002-9614-6586, Zu Eulenburg, Christine, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin. Cancer Res., 28 (22). S. 4995 - 5004. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Gluz, Oleg, Scheffen, Iris, Degenhardt, Tom, Marschner, Norbert Walter, Christgen, Matthias, Kreipe, Hans Heinrich, Nitz, Ulrike, Kates, Ronald E., Schinkoethe, Timo, Graeser, Monika Karla, Wuerstlein, Rachel, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Bauer, Lelia, Schem, Christian, Fehm, Tanja N., Neubauer, Hans and Harbeck, Nadia (2021). ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Graeser, Monika ORCID: 0000-0003-1916-717X, Feuerhake, Friedrich, Gluz, Oleg, Volk, Valery, Hauptmann, Michael, Jozwiak, Katarzyna, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kolberg-Liedtke, Cornelia, Kates, Ronald, Wuerstlein, Rachel, Nitz, Ulrike, Kreipe, Hans Heinrich and Harbeck, Nadia (2021). Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. J. Immunother. Cancer, 9 (5). LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426

Graeser, Monika ORCID: 0000-0003-1916-717X, Harbeck, Nadia, Gluz, Oleg, Wuerstlein, Rachel, zu Eulenburg, Christine, Schumacher, Claudia, Grischke, Eva -Maria, Forstbauer, Helmut, Dimpfl, Moritz ORCID: 0000-0001-6202-7397, Braun, Michael, Christgen, Matthias, Kreipe, Hans Heinrich, Potenberg, Jochem, von Schumann, Raquel, Aktas, Bahriye, Kolberg-Liedtke, Cornelia, Kuemmel, Sherko ORCID: 0000-0001-9355-494X and Nitz, Ulrike (2021). The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials. Breast, 59. S. 58 - 67. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080

Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kueemmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Nitz, Ulrike Anneliese (2017). De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J. Clin. Oncol., 35 (26). S. 3046 - 3057. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich and Nitz, Ulrike (2017). Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Braun, Michael Wilhelm, Kummel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Kleine-Tebbe, Anke, Liedtke, Cornelia, de Haas, Sanne, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg (2018). Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia ORCID: 0000-0002-9744-7372, von Schumann, Raquel, Kates, Ronald Ernest, Braun, Michael, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Schumacher, Claudia, Potenberg, Jochem, Malter, Wolfram, Augustin, Doris, Aktas, Bahriye ORCID: 0000-0002-5474-051X, Forstbauer, Helmut, Tio, Joke, Grischke, Eva-Maria, Biehl, Claudia, Liedtke, Cornelia, De Haas, Sanne Lysbet, Deurloo, Regula, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Gluz, Oleg (2021). Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers, 13 (19). BASEL: MDPI. ISSN 2072-6694

Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, Zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol., 23 (5). S. 625 - 636. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Richters, Lisa Katharina Katharina, Gluz, Oleg, Weber-Lassalle, Nana, Christgen, Matthias, Haverkamp, Heinz, Kuemmel, Sherko ORCID: 0000-0001-9355-494X, Kayali, Mohamad ORCID: 0000-0003-2092-5695, Kates, Ronald E., Grischke, Eva-Maria, Braun, Michael, Warm, Mathias, Wuerstlein, Rachel, Ernst, Corinna, Graeser, Monika Karla, Hauke, Jan, Nitz, Ulrike, Kreipe, Hans Heinrich, Schmutzler, Rita K., Hahnen, Eric and Harbeck, Nadia (2021). Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242). J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755